Formulation for menopausal women

Inactive Publication Date: 2005-05-19
DRAGTEK CORP
View PDF29 Cites 31 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0096] Another embodiment is a method for reducing the possibility of premature menopause, which comprises: administering an essential fatty acid to a woman prior to menopause, said fatty acid being selected from the group consisting of a linoleic acid compound, a linolenic

Problems solved by technology

Lack of sleep due to disturbance by recurring hot flashes contributes to fatigue and irritability.
Menopause is also characterized by osteoporosis, or loss of bone density, resulting in increased bone fractures and vertebral column collapse.
However, estrogen therapy is not without its limitations.
In some instances the side effects of estrogen therapy can be quite severe.
These side effects include increased risk of certain cancers, such as breast cancer.
Although treatments with progestin have been shown to counter these adverse side effects, postmenopausal women treated with such an estrogen-progestin regimen frequently experience undesirable uterine bleeding.
Further, hormone therapy alone is insufficient to meet the varied and heightened nutritional requirements of a woman during this phase in her life.
However, while vitamin and mineral supplements providing calcium for women is know

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Formulation for menopausal women

Examples

Experimental program
Comparison scheme
Effect test

Example

Example 1

[0171] The following formulations are used to prepare compositions for administration to premenopausal and menopausal women: ComponentDoseUnitsVitamin A (Beta Carotene)5,000I.U.Vitamin D400I.U.Vitamin E400I.U.Vitamin C100I.U.Vitamin B120mg.Vitamin B220mg.Vitamin B625mg.Vitamin B1250mcg.Vitamin B3100mg.Folic Acid1.0mg.Calcium Carbonate1,200mg.Copper2mg.Zinc15mg.Selenium65mcg.DHA / Linolenic / Linoleic Acid50 / 25 / 25mg.

[0172] It would be anticipated that upon administration of the above composition, an average normal menopausal woman would be-expected to have reduced incidence of nutritional deficiency and reduced menopausal-related symptoms or disorders when compared to an average normal menopausal woman following a conventional nutritional regimen.

Example

Example 2

[0173] The following compositions are for administration to premenopausal women and menopausal women in accordance with the regimen indicated below: RegimenComponentDoseFirst MorningCalcium Carbonate350mgTablet (orange):B Complex55mgSecond MorningCalcium Carbonate350mgTablet (white):Vitamin A3,000IUVitamin C100IUVitamin D400IUSelenium65mcgZinc15mgCooper2mgEvening TabletCalcium Carbonate350mgB Complex110mgVitamin A2,000IUFolic Acid1mgEvening CapsuleVitamin E400IUDHA50mgLinolenic Acid25mgLinoleic Acid25mgCalcium Carbonate150mg

[0174] It would be anticipated than upon following the above regimen, an average normal menopausal woman would be expected to have reduced incidence of nutritional deficiency and reduced menopausal-related symptoms or disorders when compared to an average normal menopausal woman following a conventional nutritional regimen.

Example

Example 3

[0175] A soft gelatin supplement in accordance with the compositions of Examples 1 and 2 above, may be prepared, by first combining mineral oil and soybean oil in a first vessel and blending it to form a uniform oil mixture, heating the oil mixture to 45 degrees Celsius, and then adding propylene glycol. In a second vessel preheated to 70 degrees Celsius, yellow beeswax and soybean oil are added and blended until a uniform wax mixture is formed. The wax mixture is cooled to 35 degrees Celsius and then added to the oil mixture. To this combined oil and wax mixture, folic acid, vitamin B6, iron, magnesium, and calcium are then added and blended together to form a uniform biologically active mixture. The mixture is then cooled to 30 degrees Celsius to form a viscous biologically active core composition, after which time the composition is ready for encapsulation in a soft gelatin shell.

[0176] A soft gelatin shell is prepared by heating purified water in a suitable vessel and...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Massaaaaaaaaaa
Massaaaaaaaaaa
Ratioaaaaaaaaaa
Login to view more

Abstract

The present disclosure relates to novel compositions which provide improved nutritional support for premenopausal and menopausal women and/or relief from systems associated with menopause, as well as prophylactic effects, and methods for using same.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application is a continuation application of U.S. patent application Ser. No. 10 / 131,236, filed Apr. 25, 2002; said application being a continuation of U.S. patent application Ser. No. 09 / 409,059, filed Sep. 30, 1999 now issued as U.S. Pat. No. 6,479,545, the entire contents of which are hereby incorporated by reference in their entirety.BACKGROUND OF THE INVENTION [0002] The present invention is directed to novel compositions for use by premenopausal women and menopausal women for the purpose of providing improved nutritional support and / or relief from the symptoms of menopause, as well as to methods for using same. [0003] Menopause, the transition from the reproductive stage to the non-reproductive stage of a woman's life, is characterized primarily by the cessation of menstruation. However, menopause has come to signify much more than simply the loss of reproductive capability, as it is also associated with a number of acute and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A23L1/30A23L1/304A23L33/15A61K9/10A61K9/16A61K9/20A61K9/48A61K31/07A61K31/138A61K31/194A61K31/198A61K31/201A61K31/202A61K31/355A61K31/375A61K31/4168A61K31/4415A61K31/51A61K31/525A61K31/565A61K31/566A61K31/567A61K31/57A61K31/59A61K31/616A61K31/663A61K31/714A61K33/04A61K33/06A61K33/10A61K33/18A61K33/24A61K33/26A61K33/30A61K33/32A61K33/34A61K35/32A61K35/56A61K38/23A61K45/06A61P1/08A61P1/10A61P1/12A61P5/30A61P5/34A61P9/00A61P15/00A61P15/12A61P19/02A61P21/00A61P25/02A61P25/20A61P25/22A61P25/24A61P29/02
CPCA23L1/3008A23L1/302A23L1/304A23V2002/00Y10S514/899A61K45/06A23V2250/211A23V2250/70A23V2250/156A23V2250/1868A23V2250/1874A23V2250/1872A23V2250/71A23V2250/712A23V2250/708A23V2250/704A23V2250/1578A23V2250/1588A23V2250/1642A23V2250/1626A23V2250/18A23V2250/30A23V2250/1592A23V2250/161A23V2200/224A23V2250/5432A23L33/12A23L33/15A23L33/16A61P1/08A61P1/10A61P1/12A61P15/00A61P15/12A61P19/02A61P21/00A61P25/02A61P25/20A61P25/22A61P25/24A61P29/02A61P3/02A61P5/30A61P5/34A61P9/00A61K33/06
Inventor LEVINSON, R. SAULHERMELIN, MARC S.KIRSCHNER, MITCHELL I.
Owner DRAGTEK CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products